| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Dengue | 19 | 2020 | 1565 | 2.31 | Why? |
| Singapore | 61 | 2021 | 3641 | 2.09 | Why? |
| Zika Virus Infection | 13 | 2018 | 1920 | 1.40 | Why? |
| Dengue Virus | 8 | 2018 | 910 | 1.15 | Why? |
| Dengue Vaccines | 4 | 2018 | 123 | 0.91 | Why? |
| Zika Virus | 11 | 2018 | 1924 | 0.87 | Why? |
| HIV Seropositivity | 2 | 2018 | 320 | 0.65 | Why? |
| Platelet Transfusion | 3 | 2020 | 209 | 0.65 | Why? |
| Syphilis | 1 | 2019 | 318 | 0.57 | Why? |
| Physicians, Primary Care | 1 | 2017 | 298 | 0.52 | Why? |
| Severe Acute Respiratory Syndrome | 14 | 2021 | 12361 | 0.48 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 711 | 0.45 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.43 | Why? |
| Disease Outbreaks | 15 | 2020 | 27595 | 0.41 | Why? |
| Point-of-Care Systems | 3 | 2017 | 2955 | 0.39 | Why? |
| Eye Infections, Viral | 1 | 2017 | 517 | 0.39 | Why? |
| Influenza, Human | 6 | 2020 | 10779 | 0.37 | Why? |
| Staphylococcal Infections | 1 | 2018 | 1099 | 0.37 | Why? |
| Thrombocytopenia | 2 | 2020 | 2093 | 0.34 | Why? |
| DNA, Viral | 4 | 2006 | 2521 | 0.33 | Why? |
| Diagnostic Tests, Routine | 2 | 2020 | 2643 | 0.32 | Why? |
| Endpoint Determination | 2 | 2018 | 344 | 0.32 | Why? |
| Severe Dengue | 2 | 2018 | 135 | 0.31 | Why? |
| Adult | 61 | 2021 | 244371 | 0.30 | Why? |
| Patients' Rooms | 3 | 2020 | 675 | 0.30 | Why? |
| Influenza Vaccines | 4 | 2017 | 2941 | 0.29 | Why? |
| SARS Virus | 9 | 2021 | 13021 | 0.29 | Why? |
| Population Surveillance | 3 | 2020 | 4967 | 0.28 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.28 | Why? |
| Middle Aged | 55 | 2021 | 270681 | 0.26 | Why? |
| Inappropriate Prescribing | 2 | 2017 | 284 | 0.26 | Why? |
| Epidemiological Monitoring | 1 | 2016 | 3493 | 0.26 | Why? |
| HIV Infections | 5 | 2020 | 11620 | 0.25 | Why? |
| Antibody Formation | 1 | 2017 | 4038 | 0.25 | Why? |
| Antibodies, Viral | 17 | 2021 | 51949 | 0.25 | Why? |
| Travel | 3 | 2020 | 7220 | 0.24 | Why? |
| Humans | 104 | 2021 | 930598 | 0.23 | Why? |
| Male | 59 | 2021 | 367725 | 0.23 | Why? |
| Chikungunya virus | 2 | 2018 | 339 | 0.23 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2020 | 2984 | 0.23 | Why? |
| Female | 60 | 2021 | 380317 | 0.22 | Why? |
| Immunoglobulin Class Switching | 1 | 2021 | 133 | 0.21 | Why? |
| Multilocus Sequence Typing | 2 | 2018 | 264 | 0.21 | Why? |
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2019 | 40 | 0.20 | Why? |
| Hemagglutination Inhibition Tests | 2 | 2017 | 191 | 0.20 | Why? |
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 102 | 0.20 | Why? |
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2019 | 47 | 0.20 | Why? |
| Hantavirus Infections | 1 | 2019 | 62 | 0.19 | Why? |
| Young Adult | 21 | 2020 | 93724 | 0.19 | Why? |
| Hantavirus | 1 | 2019 | 63 | 0.19 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.19 | Why? |
| Alanine | 3 | 2021 | 5687 | 0.19 | Why? |
| Public Opinion | 2 | 2020 | 1165 | 0.19 | Why? |
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 8811 | 0.19 | Why? |
| Methicillin | 1 | 2018 | 73 | 0.18 | Why? |
| Gene Deletion | 1 | 2020 | 430 | 0.18 | Why? |
| Tears | 2 | 2017 | 400 | 0.18 | Why? |
| Reagent Kits, Diagnostic | 3 | 2017 | 2149 | 0.18 | Why? |
| Aged | 36 | 2021 | 215776 | 0.18 | Why? |
| Respiratory Tract Infections | 5 | 2020 | 6817 | 0.17 | Why? |
| Streptococcus pyogenes | 1 | 2018 | 118 | 0.17 | Why? |
| Eye Protective Devices | 1 | 2020 | 245 | 0.17 | Why? |
| Monocytes | 3 | 2021 | 2978 | 0.17 | Why? |
| Capsid | 1 | 2018 | 197 | 0.17 | Why? |
| Ribavirin | 1 | 2004 | 1182 | 0.17 | Why? |
| Immunoglobulin G | 8 | 2021 | 21571 | 0.16 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.16 | Why? |
| Equivalence Trials as Topic | 1 | 2017 | 242 | 0.16 | Why? |
| Pneumonia | 1 | 2016 | 5652 | 0.16 | Why? |
| Coronavirus Infections | 22 | 2020 | 253789 | 0.16 | Why? |
| Open Reading Frames | 2 | 2020 | 1898 | 0.16 | Why? |
| Malaysia | 2 | 2020 | 1116 | 0.16 | Why? |
| Cytokines | 7 | 2021 | 15010 | 0.16 | Why? |
| Chemoprevention | 1 | 2021 | 585 | 0.16 | Why? |
| Killer Cells, Natural | 2 | 2018 | 2093 | 0.15 | Why? |
| Health Personnel | 5 | 2020 | 29646 | 0.15 | Why? |
| Arthralgia | 1 | 2018 | 173 | 0.15 | Why? |
| Serum | 1 | 2018 | 294 | 0.15 | Why? |
| Hyperlipidemias | 1 | 2018 | 290 | 0.15 | Why? |
| Severity of Illness Index | 14 | 2021 | 48226 | 0.15 | Why? |
| Culicidae | 1 | 2018 | 239 | 0.15 | Why? |
| Polymerase Chain Reaction | 5 | 2021 | 6740 | 0.15 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2021 | 13720 | 0.15 | Why? |
| Cross Infection | 5 | 2021 | 8675 | 0.15 | Why? |
| Hyaluronic Acid | 1 | 2017 | 168 | 0.15 | Why? |
| Betacoronavirus | 21 | 2020 | 204454 | 0.15 | Why? |
| Pneumonia, Viral | 22 | 2021 | 243684 | 0.15 | Why? |
| Heparitin Sulfate | 1 | 2017 | 285 | 0.15 | Why? |
| Environmental Microbiology | 1 | 2020 | 575 | 0.14 | Why? |
| Streptococcal Infections | 1 | 2018 | 255 | 0.14 | Why? |
| Delivery of Health Care | 2 | 2020 | 15909 | 0.14 | Why? |
| Adolescent | 18 | 2020 | 86841 | 0.14 | Why? |
| Rotavirus Infections | 1 | 2018 | 355 | 0.13 | Why? |
| RNA, Viral | 10 | 2021 | 32276 | 0.13 | Why? |
| Chikungunya Fever | 1 | 2018 | 345 | 0.13 | Why? |
| Focus Groups | 1 | 2017 | 811 | 0.13 | Why? |
| Metabolome | 1 | 2018 | 624 | 0.13 | Why? |
| Gastroenteritis | 1 | 2018 | 489 | 0.13 | Why? |
| Down-Regulation | 1 | 2019 | 1416 | 0.12 | Why? |
| Emigrants and Immigrants | 2 | 2020 | 888 | 0.12 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2017 | 572 | 0.12 | Why? |
| Incidence | 7 | 2021 | 25622 | 0.12 | Why? |
| Infectious Disease Incubation Period | 1 | 2020 | 1033 | 0.12 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4545 | 0.12 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2020 | 5837 | 0.12 | Why? |
| Antigens, Viral | 4 | 2017 | 6298 | 0.12 | Why? |
| Aged, 80 and over | 15 | 2020 | 88759 | 0.12 | Why? |
| Fever | 5 | 2020 | 7795 | 0.12 | Why? |
| Genotype | 3 | 2018 | 4697 | 0.11 | Why? |
| Tertiary Care Centers | 3 | 2018 | 8248 | 0.11 | Why? |
| Genome, Viral | 4 | 2020 | 13157 | 0.11 | Why? |
| Risk Assessment | 7 | 2021 | 25439 | 0.11 | Why? |
| Exanthema | 2 | 2018 | 1097 | 0.11 | Why? |
| Alphavirus Infections | 1 | 2012 | 68 | 0.11 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 7868 | 0.11 | Why? |
| Retrospective Studies | 15 | 2020 | 105322 | 0.11 | Why? |
| Government | 1 | 2020 | 1453 | 0.11 | Why? |
| Anti-Bacterial Agents | 3 | 2018 | 10083 | 0.11 | Why? |
| Volunteers | 1 | 2017 | 601 | 0.11 | Why? |
| Clinical Trials as Topic | 3 | 2020 | 7330 | 0.11 | Why? |
| Equipment Contamination | 1 | 2020 | 1308 | 0.11 | Why? |
| Rhinovirus | 1 | 2017 | 979 | 0.11 | Why? |
| Metformin | 1 | 2018 | 640 | 0.11 | Why? |
| Brain-Derived Neurotrophic Factor | 2 | 2021 | 133 | 0.11 | Why? |
| Visitors to Patients | 1 | 2017 | 671 | 0.10 | Why? |
| Time Factors | 9 | 2021 | 31397 | 0.10 | Why? |
| Contact Tracing | 5 | 2020 | 8448 | 0.10 | Why? |
| Sexual Behavior | 1 | 2019 | 1322 | 0.10 | Why? |
| Trust | 1 | 2020 | 1487 | 0.10 | Why? |
| Viral Nonstructural Proteins | 2 | 2018 | 4810 | 0.10 | Why? |
| Neutrophils | 3 | 2021 | 5476 | 0.10 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.10 | Why? |
| Patient Isolation | 2 | 2020 | 3182 | 0.10 | Why? |
| Risk Factors | 10 | 2020 | 71621 | 0.10 | Why? |
| Lysosomal-Associated Membrane Protein 1 | 2 | 2019 | 27 | 0.10 | Why? |
| Histocompatibility Antigens Class I | 1 | 2014 | 624 | 0.10 | Why? |
| Immunization Schedule | 1 | 2017 | 1305 | 0.10 | Why? |
| Patients | 1 | 2017 | 1167 | 0.10 | Why? |
| Health Education | 2 | 2020 | 1539 | 0.10 | Why? |
| Double-Blind Method | 1 | 2020 | 5988 | 0.10 | Why? |
| Carrier State | 1 | 2021 | 2100 | 0.10 | Why? |
| Macrophages | 2 | 2018 | 2784 | 0.09 | Why? |
| Medical Audit | 1 | 2010 | 218 | 0.09 | Why? |
| B-Lymphocytes | 2 | 2021 | 4418 | 0.09 | Why? |
| Occupational Diseases | 1 | 2004 | 2787 | 0.09 | Why? |
| Treatment Outcome | 9 | 2021 | 51732 | 0.09 | Why? |
| Antimicrobial Stewardship | 1 | 2017 | 931 | 0.09 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| Orthomyxoviridae | 1 | 2016 | 1168 | 0.09 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.09 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.09 | Why? |
| Infant | 6 | 2020 | 30274 | 0.09 | Why? |
| Child, Preschool | 6 | 2020 | 36283 | 0.09 | Why? |
| Immunoglobulin M | 4 | 2021 | 9091 | 0.09 | Why? |
| Convalescence | 2 | 2017 | 2829 | 0.09 | Why? |
| Longitudinal Studies | 3 | 2018 | 9893 | 0.09 | Why? |
| Child | 10 | 2020 | 70012 | 0.09 | Why? |
| Antiviral Agents | 6 | 2021 | 41703 | 0.08 | Why? |
| Personal Protective Equipment | 3 | 2020 | 15978 | 0.08 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.08 | Why? |
| Immunologic Tests | 2 | 2021 | 445 | 0.08 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.08 | Why? |
| Immunologic Memory | 1 | 2018 | 3362 | 0.08 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.08 | Why? |
| Fluorescent Antibody Technique | 2 | 2006 | 835 | 0.08 | Why? |
| Health Surveys | 1 | 2017 | 2841 | 0.08 | Why? |
| Antibodies, Neutralizing | 3 | 2020 | 25288 | 0.08 | Why? |
| Dendritic Cells | 1 | 2014 | 1330 | 0.07 | Why? |
| Immunogenicity, Vaccine | 2 | 2021 | 4624 | 0.07 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.07 | Why? |
| Guillain-Barre Syndrome | 1 | 2018 | 1495 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.07 | Why? |
| Pandemics | 23 | 2020 | 389249 | 0.07 | Why? |
| Influenza A virus | 1 | 2017 | 2234 | 0.07 | Why? |
| Bacteremia | 1 | 2015 | 1372 | 0.07 | Why? |
| Tuberculosis | 1 | 2020 | 2895 | 0.07 | Why? |
| Cells, Cultured | 4 | 2018 | 5835 | 0.07 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2014 | 2483 | 0.07 | Why? |
| Aging | 1 | 2020 | 3581 | 0.07 | Why? |
| Radiography | 2 | 2020 | 1576 | 0.07 | Why? |
| Personnel, Hospital | 1 | 2017 | 2273 | 0.07 | Why? |
| Nasopharynx | 2 | 2020 | 10224 | 0.07 | Why? |
| Cohort Studies | 4 | 2018 | 36005 | 0.06 | Why? |
| Coronavirus | 4 | 2020 | 18339 | 0.06 | Why? |
| Epidemics | 3 | 2020 | 6407 | 0.06 | Why? |
| Infection Control | 4 | 2020 | 23131 | 0.06 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Virus Diseases | 1 | 2020 | 3779 | 0.06 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| Case-Control Studies | 5 | 2021 | 17671 | 0.06 | Why? |
| Communicable Diseases, Emerging | 2 | 2010 | 2523 | 0.06 | Why? |
| Diagnosis, Differential | 3 | 2018 | 7220 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.06 | Why? |
| Medical Laboratory Personnel | 1 | 2004 | 254 | 0.06 | Why? |
| Biomarkers | 6 | 2021 | 23361 | 0.06 | Why? |
| Intensive Care Units | 4 | 2021 | 29594 | 0.06 | Why? |
| Flow Cytometry | 2 | 2021 | 2393 | 0.06 | Why? |
| Vascular Endothelial Growth Factor D | 1 | 2021 | 38 | 0.06 | Why? |
| Phylogeny | 4 | 2021 | 13341 | 0.06 | Why? |
| Primary Health Care | 2 | 2017 | 4839 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2017 | 4927 | 0.06 | Why? |
| Interferon Type I | 1 | 2014 | 2789 | 0.05 | Why? |
| Seroconversion | 2 | 2021 | 2515 | 0.05 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Serologic Tests | 3 | 2020 | 4359 | 0.05 | Why? |
| Viral Load | 6 | 2021 | 15850 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2020 | 29620 | 0.05 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 9706 | 0.05 | Why? |
| Sentinel Surveillance | 2 | 2018 | 1093 | 0.05 | Why? |
| Subcellular Fractions | 1 | 2019 | 25 | 0.05 | Why? |
| Cross-Sectional Studies | 5 | 2020 | 53120 | 0.05 | Why? |
| Cytoprotection | 1 | 2019 | 44 | 0.05 | Why? |
| AIDS Serodiagnosis | 1 | 2000 | 64 | 0.05 | Why? |
| Sampling Studies | 1 | 2020 | 386 | 0.05 | Why? |
| Evaluation Studies as Topic | 1 | 2021 | 391 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2017 | 4741 | 0.05 | Why? |
| Proteasome Inhibitors | 1 | 2019 | 127 | 0.05 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2020 | 8843 | 0.05 | Why? |
| Immunization Programs | 1 | 2011 | 2006 | 0.05 | Why? |
| Asymptomatic Diseases | 2 | 2021 | 3444 | 0.04 | Why? |
| Proteasome Endopeptidase Complex | 1 | 2019 | 249 | 0.04 | Why? |
| Network Meta-Analysis | 1 | 2020 | 426 | 0.04 | Why? |
| Immunity, Heterologous | 1 | 2018 | 129 | 0.04 | Why? |
| Ubiquitination | 1 | 2019 | 343 | 0.04 | Why? |
| Asthma | 1 | 2017 | 4383 | 0.04 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.04 | Why? |
| Virus Replication | 4 | 2020 | 14331 | 0.04 | Why? |
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 286 | 0.04 | Why? |
| Sequence Analysis, DNA | 2 | 2004 | 2830 | 0.04 | Why? |
| Pamphlets | 1 | 2017 | 27 | 0.04 | Why? |
| Masks | 1 | 2020 | 8528 | 0.04 | Why? |
| World Health Organization | 2 | 2021 | 4213 | 0.04 | Why? |
| ROC Curve | 2 | 2021 | 6024 | 0.04 | Why? |
| Seroepidemiologic Studies | 2 | 2020 | 10017 | 0.04 | Why? |
| Cell Death | 1 | 2019 | 536 | 0.04 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Respiratory Rate | 1 | 2021 | 691 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.04 | Why? |
| Congresses as Topic | 2 | 2020 | 1347 | 0.04 | Why? |
| Vaccination | 3 | 2017 | 19050 | 0.04 | Why? |
| Lymphocyte Depletion | 1 | 2018 | 293 | 0.04 | Why? |
| Cross Reactions | 2 | 2018 | 4374 | 0.04 | Why? |
| Transcriptome | 2 | 2021 | 3466 | 0.04 | Why? |
| Reassortant Viruses | 1 | 2018 | 287 | 0.04 | Why? |
| Sequence Deletion | 1 | 2020 | 674 | 0.04 | Why? |
| Th17 Cells | 1 | 2021 | 657 | 0.04 | Why? |
| Hypoxia | 2 | 2021 | 3626 | 0.04 | Why? |
| Immunophenotyping | 1 | 2020 | 1290 | 0.04 | Why? |
| Likelihood Functions | 1 | 2018 | 719 | 0.04 | Why? |
| Databases, Nucleic Acid | 1 | 2018 | 272 | 0.04 | Why? |
| RNA Helicases | 1 | 2018 | 413 | 0.04 | Why? |
| Mosquito Vectors | 1 | 2018 | 351 | 0.04 | Why? |
| Immunodominant Epitopes | 1 | 2020 | 813 | 0.04 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.04 | Why? |
| Respiration, Artificial | 4 | 2021 | 22116 | 0.04 | Why? |
| Clinical Decision-Making | 2 | 2021 | 3755 | 0.04 | Why? |
| Cross Protection | 1 | 2017 | 373 | 0.04 | Why? |
| Animals | 7 | 2018 | 78931 | 0.04 | Why? |
| Rotavirus | 1 | 2018 | 329 | 0.04 | Why? |
| Hospitals | 3 | 2021 | 11793 | 0.04 | Why? |
| Particle Size | 1 | 2020 | 1052 | 0.04 | Why? |
| Fas Ligand Protein | 1 | 2014 | 69 | 0.04 | Why? |
| Aedes | 1 | 2018 | 380 | 0.04 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2020 | 11367 | 0.03 | Why? |
| Factor Analysis, Statistical | 1 | 2017 | 538 | 0.03 | Why? |
| fas Receptor | 1 | 2014 | 85 | 0.03 | Why? |
| Diabetes Mellitus | 1 | 2017 | 8207 | 0.03 | Why? |
| Cell Membrane | 1 | 2019 | 743 | 0.03 | Why? |
| Immunization, Passive | 2 | 2020 | 10067 | 0.03 | Why? |
| Granzymes | 1 | 2014 | 197 | 0.03 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.03 | Why? |
| Perforin | 1 | 2014 | 136 | 0.03 | Why? |
| Coculture Techniques | 1 | 2014 | 258 | 0.03 | Why? |
| Receptors, IgG | 1 | 2018 | 578 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Systems Analysis | 1 | 2017 | 366 | 0.03 | Why? |
| Cattle | 1 | 2018 | 1336 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Conjunctivitis, Viral | 1 | 2018 | 301 | 0.03 | Why? |
| Interleukin-10 | 1 | 2020 | 1409 | 0.03 | Why? |
| Respiratory Therapy | 1 | 2020 | 918 | 0.03 | Why? |
| A549 Cells | 1 | 2019 | 2066 | 0.03 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.03 | Why? |
| Regression Analysis | 1 | 2020 | 2484 | 0.03 | Why? |
| Ventilation | 1 | 2020 | 1145 | 0.03 | Why? |
| Cytotoxicity, Immunologic | 1 | 2014 | 287 | 0.03 | Why? |
| L-Lactate Dehydrogenase | 1 | 2021 | 1995 | 0.03 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.03 | Why? |
| Hospitals, Psychiatric | 1 | 2018 | 506 | 0.03 | Why? |
| Myalgia | 1 | 2018 | 1015 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
| Cell Communication | 1 | 2014 | 396 | 0.03 | Why? |
| Epitopes, B-Lymphocyte | 1 | 2020 | 1267 | 0.03 | Why? |
| Base Sequence | 1 | 2020 | 3581 | 0.03 | Why? |
| Platelet Count | 1 | 2018 | 1381 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2018 | 1165 | 0.03 | Why? |
| Sputum | 1 | 2020 | 1720 | 0.03 | Why? |
| Fomites | 1 | 2018 | 709 | 0.03 | Why? |
| Proportional Hazards Models | 1 | 2004 | 6543 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Conjunctiva | 1 | 2017 | 620 | 0.03 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.03 | Why? |
| Survival Rate | 1 | 2006 | 9206 | 0.03 | Why? |
| Crowding | 1 | 2017 | 731 | 0.03 | Why? |
| Decontamination | 1 | 2020 | 1196 | 0.03 | Why? |
| Laboratories | 1 | 2004 | 2858 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Health Planning Guidelines | 1 | 2011 | 133 | 0.03 | Why? |
| Thorax | 1 | 2020 | 1873 | 0.03 | Why? |
| Membrane Proteins | 1 | 2021 | 1733 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.03 | Why? |
| Blood Transfusion | 1 | 2000 | 1399 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| BCG Vaccine | 1 | 2020 | 1137 | 0.03 | Why? |
| Family Characteristics | 1 | 2020 | 2551 | 0.02 | Why? |
| Uncertainty | 1 | 2021 | 1888 | 0.02 | Why? |
| Residence Characteristics | 1 | 2020 | 1927 | 0.02 | Why? |
| Cough | 1 | 2003 | 4891 | 0.02 | Why? |
| Feces | 2 | 2018 | 4235 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.02 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.02 | Why? |
| Viral Vaccines | 2 | 2020 | 7560 | 0.02 | Why? |
| Sequence Analysis, RNA | 1 | 2018 | 2290 | 0.02 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2017 | 1439 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Mice | 2 | 2018 | 21357 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2020 | 6049 | 0.02 | Why? |
| Leukocyte Count | 1 | 2018 | 3178 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2018 | 2742 | 0.02 | Why? |
| Plasma | 1 | 2018 | 1809 | 0.02 | Why? |
| Personnel Staffing and Scheduling | 1 | 2017 | 1578 | 0.02 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.02 | Why? |
| Urban Population | 1 | 2018 | 2000 | 0.02 | Why? |
| Particulate Matter | 1 | 2020 | 3249 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
| Guideline Adherence | 1 | 2020 | 2309 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2018 | 2262 | 0.02 | Why? |
| Medical Staff, Hospital | 1 | 2017 | 1258 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.02 | Why? |
| Disinfection | 1 | 2020 | 2912 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Public Health | 3 | 2020 | 16359 | 0.02 | Why? |
| Proteomics | 1 | 2018 | 2481 | 0.02 | Why? |
| Blood Donors | 1 | 2000 | 2956 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Skin | 1 | 2018 | 2096 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.02 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| HIV-1 | 1 | 2000 | 3365 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Disaster Planning | 1 | 2017 | 1680 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Asia | 1 | 2011 | 2399 | 0.02 | Why? |
| Immune Evasion | 1 | 2014 | 2081 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.02 | Why? |
| Biomedical Research | 1 | 2004 | 5270 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Quarantine | 2 | 2020 | 18418 | 0.02 | Why? |
| Serine Endopeptidases | 1 | 2018 | 4606 | 0.01 | Why? |
| Immunoassay | 1 | 2018 | 4485 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Survival Analysis | 1 | 2015 | 7592 | 0.01 | Why? |
| Gene Expression Regulation | 1 | 2014 | 4020 | 0.01 | Why? |
| Viral Proteins | 1 | 2000 | 7370 | 0.01 | Why? |
| Lung | 2 | 2020 | 31049 | 0.01 | Why? |
| Genes, env | 1 | 2000 | 17 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.01 | Why? |
| Gene Products, gag | 1 | 2000 | 28 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Gene Amplification | 1 | 2000 | 85 | 0.01 | Why? |
| Plasmids | 1 | 2004 | 840 | 0.01 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Hospital Mortality | 1 | 2004 | 22087 | 0.01 | Why? |
| HIV Antigens | 1 | 2000 | 102 | 0.01 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2000 | 95 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Antibody Specificity | 1 | 2004 | 1328 | 0.01 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
| Signal Transduction | 1 | 2014 | 7207 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.01 | Why? |
| Erythrocyte Transfusion | 1 | 2000 | 386 | 0.01 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 1997 | 260 | 0.01 | Why? |
| False Negative Reactions | 1 | 2000 | 1785 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.01 | Why? |
| Immunoglobulin A | 1 | 2004 | 3567 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |
| Prognosis | 1 | 2012 | 32490 | 0.01 | Why? |
| Heart Diseases | 1 | 2004 | 3503 | 0.00 | Why? |